[FUJIFILM Cellular Dynamics, Inc.] FUJIFILM Cellular Dynamics, Inc. celebrated the opening of its new headquarters and iPSC development and manufacturing facility in its Madison home. The new site is expected to quadruple the capacity for the company’s iPSC-based research products and services manufacturing footprint and expand capabilities across FUJIFILM Cellular Dynamics’ research product portfolio.

[Proceedings of the National Academy of Sciences of the United States of America] Scientists highlighted how spherical epithelial shells, formed from hiPSCs, achieve “superdeformability” through reversible bending and tilting of their lateral cell edges.

[NPJ Parkinson'S Disease] Investigators developed an optimized protocol building upon our previously established neural induction method, with further refinements, to efficiently convert iPSCs into midbrain dopaminergic neurons.

[Cell Death Discovery] Using mESC as an inner cell mass model, the authors showed that replication stress rapidly and durably induces trophoectoderm regulators, including Cdx2, Gata3, Eomes, Elf5, Hand1, and Tfap2c.

[Archives of Toxicology] Researchers evaluated the effects and potential mechanism of selected pyrethroids and their common metabolite 3-PBA on cardiomyocyte differentiation.

[iScience] Investigators used a hiPSC model to compare differentiation of cranial neural crest cells (NCCs) and trunk NCCs and define lineage specific mechanisms.

[iScience] Researchers examined the remodeling of central and xenobiotic metabolism during the glycine-supplemented differentiation of iPSCs into hepatocyte-like cells and HepG2 into a metabolically active form.

[Inflammation and Regeneration] Scientists outline their research trajectory, transitioning from the foundational autologous “T-iPSC” concept to scalable, “off-the-shelf” allogeneic strategies.

[Stem Cell Reviews and Reports] The authors summarize current strategies for iPSC-to- natural killer differentiation, spanning feeder-based systems, feeder-free protocols, embryoid body approaches, and scalable GMP-compatible manufacturing methods.

[Secretome Therapeutics (Business Wire)] Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), today announced the closing of a $30 million Series A financing from RA Capital Management, LP (“RA Capital”), a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies. RA Capital was the sole investor in the financing.

[Proceedings of the National Academy of Sciences of the United States of America] Researchers developed a screening platform using hiPSC–derived cardiomyocytes to identify human cardiotropic lipid nanoparticles (LNPs). By screening a chemically diverse LNP library, they identified a lead LNP, 18:1 TAP10, with potent human cardiac transfection capability.

[Cell Reports] Scientists investigated the impact of maternal hyperglycemia on cardiac development using a diabetic pregnancy mouse model and pluripotent stem cell-derived cardiomyocytes.